Joshua Davidson
Optometrist · Gonzales, LANPI 1881026003
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 30.1% of the total. Among optometrist clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 672 payments — averaging $281.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$57K
- AbbVie$54K
- Eyevance Pharmaceuticals LLC$27K
- Dompe US, Inc.$11K
- Kala Pharmaceuticals, Inc.$10K
- Alcon$8K
- plus $23K from 26 others
What the payments were for
- Consulting fees$46,89925%
- Speaking & faculty fees$99,53853%
- Travel & lodging$22,45112%
- Food & beverage$20,07211%
- Entertainment$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 123 | $56,900 |
| AbbVie(2 entities) | 112 | $53,891 |
| Eyevance Pharmaceuticals LLC | 47 | $26,723 |
| Dompe US, Inc. | 23 | $10,597 |
| Kala Pharmaceuticals, Inc. | 21 | $9,987 |
| Alcon | 50 | $7,565 |
| Glaukos Corporation | 30 | $6,329 |
| Oyster Point Pharma, Inc. | 39 | $3,567 |
| Tearlab Corp | 2 | $2,500 |
| Sun Pharmaceutical Industries Inc. | 47 | $2,033 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $1,752 |
| Johnson & Johnson Vision Care, Inc. | 32 | $1,704 |
| Tarsus Pharmaceuticals, Inc. | 16 | $1,219 |
| Novartis | 49 | $1,182 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $538 |
| Alcon Research LLC | 1 | $500 |
| Harrow Eye, LLC | 11 | $397 |
| Biotissue Holdings Inc. | 15 | $371 |
| Quidel Corporation | 6 | $232 |
| Mallinckrodt Hospital Products Inc. | 5 | $207 |
| Optos, Inc. | 3 | $183 |
| Rxsight Inc | 4 | $128 |
| Amgen | 1 | $116 |
| Shire North American Group Inc | 3 | $108 |
| Thea Pharma Inc. | 1 | $71 |
| Coopervision Inc. | 3 | $52 |
| Sight Sciences, Inc. | 2 | $36 |
| Rayner Intraocular Lenses Limited | 1 | $31 |
| Ivantis, Inc | 2 | $30 |
| Aerie Pharmaceuticals, Inc. | 1 | $29 |
| NEW World Medical,inc. | 1 | $18 |
| Ocular Therapeutix, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$51,459
- VUITY$49,648
- XIIDRA$47,191
- Flarex$19,426
- Oxervate$10,169
- EYSUVIS$9,463
- TRYPTYR$5,553
- Zerviate$3,750
- Tobradex ST$3,000
- INFUSE$2,786
- TYRVAYA$2,540
- TearLab Osmolarity System$2,500
- iStent inject Trabecular Micro-Bypass Stent System$1,853
- BIOTRUE$1,161
- ULTRA$1,161
- CEQUA$987
- Acuvue$927
- CE-marked KXLA system$525
- BLINK NUTRITEARS$500
- Tecnis IOL$450
How this compares
$189,009 in reported general payments places this provider in the 95th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 17 | $705,830 |
| RestasisCyclosporine | 394 | $293,949 |
| XiidraLifitegrast | 273 | $205,763 |
| CequaCyclosporine | 130 | $78,964 |
| XdemvyLotilaner | 20 | $38,779 |
| MieboPerfluorohexyloctane/Pf | 28 | $22,236 |
| TyrvayaVarenicline Tartrate | 13 | $17,762 |
| LumiganBimatoprost | 35 | $16,127 |
| Cyclosporine | 28 | $9,854 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $9,355 |
| VyzultaLatanoprostene Bunod | 25 | $7,524 |
| Fluorometholone | 105 | $6,764 |
| Restasis MultidoseCyclosporine | 11 | $6,411 |
| Prednisolone Acetate | 149 | $4,929 |
| Latanoprost | 150 | $1,694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $10,597 | $705,83017 claims |
| AbbVieRestasis, Lumigan, Combigan, Restasis Multidose, Vuity | $53,891 | $326,981485 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $56,900 | $235,523326 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $2,033 | $78,964130 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,219 | $38,77920 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $3,567 | $17,76213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Gonzales
- Lawrence PhamGonzales$9K
- Eva LamendolaGonzales$8K
- Edwin AdamsGonzales$6K
- Heaven HarrisGonzales$5K
- Matthew BarnesGonzales$5K
- Pamela TheriotShreveport$207K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.